DK0997145T3 - Fremgangsmåde til at identificere forbindelser til inhibering af neoplastiske læsioner - Google Patents

Fremgangsmåde til at identificere forbindelser til inhibering af neoplastiske læsioner

Info

Publication number
DK0997145T3
DK0997145T3 DK99308129T DK99308129T DK0997145T3 DK 0997145 T3 DK0997145 T3 DK 0997145T3 DK 99308129 T DK99308129 T DK 99308129T DK 99308129 T DK99308129 T DK 99308129T DK 0997145 T3 DK0997145 T3 DK 0997145T3
Authority
DK
Denmark
Prior art keywords
compound
activity
determining
pde
cox
Prior art date
Application number
DK99308129T
Other languages
Danish (da)
English (en)
Inventor
Li Liu
Bing Zhu
Joseph W Thompson
Rifat Pamukeu
Gary A Piazza
Li Han
Original Assignee
Cell Pathways Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/173,375 external-priority patent/US6200771B1/en
Priority claimed from US09/366,003 external-priority patent/US6130053A/en
Priority claimed from US09/414,628 external-priority patent/US20020009764A1/en
Application filed by Cell Pathways Inc filed Critical Cell Pathways Inc
Application granted granted Critical
Publication of DK0997145T3 publication Critical patent/DK0997145T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK99308129T 1998-10-15 1999-10-14 Fremgangsmåde til at identificere forbindelser til inhibering af neoplastiske læsioner DK0997145T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/173,375 US6200771B1 (en) 1998-10-15 1998-10-15 Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US09/366,003 US6130053A (en) 1999-08-03 1999-08-03 Method for selecting compounds for inhibition of neoplastic lesions
US09/414,628 US20020009764A1 (en) 1999-10-08 1999-10-08 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds

Publications (1)

Publication Number Publication Date
DK0997145T3 true DK0997145T3 (da) 2002-07-29

Family

ID=27390268

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99308129T DK0997145T3 (da) 1998-10-15 1999-10-14 Fremgangsmåde til at identificere forbindelser til inhibering af neoplastiske læsioner

Country Status (13)

Country Link
EP (2) EP0997145B1 (fr)
JP (1) JP2000186047A (fr)
CN (1) CN100389829C (fr)
AT (1) ATE214920T1 (fr)
AU (1) AU770308B2 (fr)
CA (1) CA2284853A1 (fr)
DE (1) DE69901082T2 (fr)
DK (1) DK0997145T3 (fr)
ES (1) ES2174573T3 (fr)
IL (1) IL132366A0 (fr)
NO (2) NO994995L (fr)
TR (1) TR199902578A3 (fr)
TW (1) TWI239837B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531826A (ja) * 1998-11-25 2002-09-24 セル パスウェイズ インコーポレイテッド 新形成診断法
US6569638B1 (en) * 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
EP1313727A1 (fr) * 2000-08-21 2003-05-28 AstraZeneca AB Derives de quinazoline
EP1597386A1 (fr) * 2002-11-13 2005-11-23 Bayer HealthCare AG Outils de diagnostics et therapeutique pour maladies associees a la phosphodiesterase 2a humaine (pde2a)
DK1670444T3 (da) 2003-10-03 2011-08-22 Veijlen N V Anvendelse af IFG-1-serumniveau forhøjende indoleddikesyrederivater til fremstilling af en lægemiddelsammensætning til behandling af forskellige sygdomme
WO2005054181A1 (fr) * 2003-12-01 2005-06-16 Reverse Proteomics Research Institute Co., Ltd. Nouvelle proteine cible d'un agent anticancereux et nouvel agent anticancereux (spnal) correspondant a cette proteine
JP5219135B2 (ja) * 2008-07-25 2013-06-26 独立行政法人産業技術総合研究所 炎症性疾患モデル動物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650720B2 (en) * 1991-03-08 1994-06-30 Fgn, Inc. Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5998477A (en) * 1996-06-13 1999-12-07 Cell Pathways Inc. Substituted methoxy benzylidene indenyl-acetic and propionic acids for treating patients with precancerous lesions
US6063818A (en) * 1996-06-13 2000-05-16 Cell Pathways Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides
ATE301459T1 (de) * 1996-09-18 2005-08-15 Applied Genetics Inc Dermatics Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen
CA2238283C (fr) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Methode d'identification de composes visant a inhiber les lesions neoplasiques, compositions pharmaceutiques a prtir de ces composes et compositions pour traiter les lesions neoplasiques
US5922595A (en) * 1997-12-09 1999-07-13 Incyte Pharmaceuticals, Inc. Cyclic GMP phosphodiesterase
ES2212383T3 (es) * 1997-12-12 2004-07-16 Osi Pharmaceuticals, Inc. Derivados de n-bencil-3-indenilacetamidas para el tratamiento de neoplasias.

Also Published As

Publication number Publication date
EP1161943A3 (fr) 2003-12-10
ES2174573T3 (es) 2002-11-01
NO994995D0 (no) 1999-10-14
TR199902578A2 (xx) 2000-06-21
IL132366A0 (en) 2001-03-19
DE69901082T2 (de) 2002-08-29
CN100389829C (zh) 2008-05-28
TR199902578A3 (tr) 2000-06-21
AU5401099A (en) 2000-04-20
NO20062682L (no) 2000-04-17
JP2000186047A (ja) 2000-07-04
EP0997145A1 (fr) 2000-05-03
CN1255379A (zh) 2000-06-07
TWI239837B (en) 2005-09-21
EP0997145B1 (fr) 2002-03-27
AU770308B2 (en) 2004-02-19
NO994995L (no) 2000-04-17
CA2284853A1 (fr) 2000-04-15
EP1161943A2 (fr) 2001-12-12
ATE214920T1 (de) 2002-04-15
DE69901082D1 (de) 2002-05-02

Similar Documents

Publication Publication Date Title
NO20062682L (no) Farmasoytiske blandinger inneholdende forbindelser for inhibering av neoplastiske lesjoner
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
NO971684L (no) Nye benzoxazoler
DK0770065T3 (da) Trisubstituerede phenylderivater nyttige som PDE IV-inhibitorer
BR0317183A (pt) Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
DE60009511D1 (de) Nematizide trifluorbutene
YU76401A (sh) 1-amino triazolo(4,3-a)hinazolin-5-oni i/ili - 5-tioni koji inhibiraju fosfodiesteraze iv
DK0881300T3 (da) Metode til at identificere forbindelser til inhibition af neoplastiske læsioner
ATE266013T1 (de) 1-phenyl-4-benzylpiperazine: spezifische liganden für den dopamin rezeptor (d4)
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
WO2003030886A3 (fr) Allylamides utilises dans le traitement de la maladie d'alzheimer
HUP0102615A2 (hu) 2-(2-Klór-fenil)-3,4-dihidro-2H-pirrol-származékok
ATE326964T1 (de) Aminosäurederivate zur behandlung der alzheimer- krankheit
MXPA03011399A (es) Metodos para tratar la enfermedad de alzheimer.
NO308829B1 (no) Anvendelse av forbindelsen finasterid for fremstilling av et preparat for behandling av kronisk prostatitt hos menn
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
BR0307266A (pt) Compostos que inibem a atividade do fator xa
NZ512546A (en) Use of actylcholine esterase inhibitors to treat delirium
ES2185154T3 (es) Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de la demencia.
CO4940455A1 (es) Compuestos para la inhibicion de la transferasa de proteina de farnesilo
MXPA04000139A (es) Uso de compuestos biciclo para tratar enfermedad de alzheimer.
ECSP982536A (es) Compuestos utiles para la inhibicion de transferasa de proteina al farnesilo ( case ino750k)
ATE402693T1 (de) Fab i und hemmung von apicomplexan-parasiten